PEG-ilodecakin

N/A

Report date: 2025/03/05 20:00:52

Base Information

Drug NamePEG-ilodecakin
Drug Alias NamePEGylated Human IL-10PEGylated recombinant human Interleukin-10PEGylated Interleukin-10PegilodecakinPEG-rHuIL-10 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin 10 receptor stimulantsImmunomodulators
TargetsInterleukin 10 receptor
Therapy Area/IndicationsSolid tumoursVasculitisGranulomatosis with Polyangiitis +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme CorpArmo Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesArmo BiosciencesEli Lilly And Company
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[7] 
Inactive IndicationsVasculitisGranulomatosis with PolyangiitisCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksN/A